Fluoxetine, the generic name for Prozac, is available from multiple manufacturers. When seeking generic fluoxetine, consumers will find a range of brands produced by different pharmaceutical companies.
What companies make generic fluoxetine?
Several companies manufacture generic fluoxetine. These include Teva Pharmaceuticals, Aurobindo Pharma, Accord Healthcare, and Mylan (now Viatris), among others. The availability of specific brands can vary by pharmacy and region.
When did fluoxetine go off patent?
Fluoxetine's patent protections expired many years ago, allowing for the widespread introduction of generic versions. The original patent for fluoxetine was issued in the 1970s, and its market exclusivity ended in the early 2000s [1].
How does generic fluoxetine differ from brand-name Prozac?
Generic fluoxetine is bioequivalent to brand-name Prozac, meaning it contains the same active ingredient, dosage form, strength, and route of administration. The primary differences are typically in the inactive ingredients, such as fillers, dyes, and binders, which can affect appearance and sometimes cost [2]. The U.S. Food and Drug Administration (FDA) requires generic drugs to meet the same standards of safety and efficacy as their brand-name counterparts [2].
Are there different formulations of generic fluoxetine?
Generic fluoxetine is available in several forms, including capsules, tablets, and oral solutions. These formulations allow patients to choose the most convenient and suitable option for their needs.
What is the cost difference between generic and brand-name fluoxetine?
Generic fluoxetine is generally significantly less expensive than brand-name Prozac. The introduction of multiple generic manufacturers increases market competition, driving down prices for consumers.
Where can I find information on drug patent expirations?
Information on drug patent expirations, including those for antidepressants like fluoxetine, can be found on resources like DrugPatentWatch.com [1]. This site provides data on patent status and exclusivity periods for pharmaceutical products.
---
Sources
1. DrugPatentWatch.com
2. U.S. Food and Drug Administration